PubRank

R A Lubet

Author PubWeight™ 108.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000 1.96
2 Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999 1.95
3 Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000 1.84
4 Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996 1.77
5 Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000 1.69
6 Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 1990 1.56
7 Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A 2000 1.54
8 Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1999 1.49
9 Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys 1985 1.28
10 Effects of sublethal gamma radiation on T and B cell activity in the antibody response of mice. Radiat Res 1976 1.23
11 Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000 1.12
12 Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. Carcinogenesis 2001 1.10
13 Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999 1.10
14 A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res 2000 1.07
15 Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999 1.07
16 Characterization of a cloned human dihydrotestosterone/androstanediol UDP-glucuronosyltransferase and its comparison to other steroid isoforms. Biochemistry 1993 1.04
17 Chemoprevention of prostate cancer: concepts and strategies. Eur Urol 1999 1.04
18 Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994 1.03
19 Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 1996 1.01
20 New agents for cancer chemoprevention. J Cell Biochem Suppl 1996 1.00
21 Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res 1998 0.99
22 Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res 1999 0.97
23 The effect of vitamin E acetate on ultraviolet-induced mouse skin carcinogenesis. Mol Carcinog 1998 0.96
24 Progress in cancer chemoprevention. Ann N Y Acad Sci 1999 0.95
25 Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999 0.95
26 Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 1996 0.94
27 Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res 1999 0.94
28 Biological effects of the Sudan dyes. Role of the Ah cytosolic receptor. Biochem Pharmacol 1983 0.92
29 Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis 1999 0.92
30 Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. Cancer Res 1999 0.92
31 Measurement of cytochrome P-450 dependent dealkylation of alkoxyphenoxazones in hepatic S9s and hepatocyte homogenates: effects of dicumarol. Mutat Res 1985 0.91
32 A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. Oncogene 2006 0.91
33 Two human liver cDNAs encode UDP-glucuronosyltransferases with 2 log differences in activity toward parallel substrates including hyodeoxycholic acid and certain estrogen derivatives. Biochemistry 1992 0.90
34 Formation and persistence of nucleotide alterations in rats exposed whole-body to environmental cigarette smoke. Carcinogenesis 1999 0.90
35 Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours. Eur J Cancer 2003 0.90
36 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis 1999 0.90
37 Dibenz[a,h]anthracene-induced subcutaneous tumors in mice. Strain sensitivity and the role of carcinogen metabolism. Carcinogenesis 1983 0.89
38 Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochem Pharmacol 1993 0.89
39 Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1996 0.89
40 Modulation of biomarkers by chemopreventive agents in smoke-exposed rats. Cancer Res 2001 0.88
41 Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp Lung Res 2000 0.88
42 K-ras mutations in lung tumors from A/J and A/J x TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis 1995 0.88
43 Tumor-promoting and hepatocarcinogenic effects of 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine. Carcinogenesis 1992 0.87
44 Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 1996 0.87
45 Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004 0.86
46 Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1998 0.85
47 Preferential decrease in thymus dependent lymphocytes during storage at 4 C in anticoagulant. Transfusion 1977 0.85
48 Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J Cell Biochem Suppl 1994 0.85
49 Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer Res 1996 0.85
50 Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and their modulation of cell proliferation in the colon of rats. Carcinogenesis 1997 0.84
51 Induction of cytochrome P-450 in the Norway rat, Rattus norvegicus, following exposure to potential environmental contaminants. J Toxicol Environ Health 1995 0.84
52 Genetic alterations in mouse lung tumors: implications for cancer chemoprevention. J Cell Biochem Suppl 1997 0.83
53 Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001 0.83
54 Preclinical drug development paradigms for chemopreventives. Hematol Oncol Clin North Am 1998 0.83
55 Pilot studies evaluating the lung tumor yield in cigarette smoke-exposed mice. Int J Oncol 2001 0.83
56 Effect of the aromatase inhibitor vorozole on estrogen and progesterone receptor content of rat mammary carcinomas induced by 1-methyl-1-nitrosourea. Breast Cancer Res Treat 2001 0.83
57 Chemical enhancement of SA7 virus transformation of hamster embryo cells: evaluation by interlaboratory testing of diverse chemicals. Environ Mutagen 1986 0.83
58 Chemopreventive efficacy of promising farnesyltransferase inhibitors. Exp Lung Res 2000 0.83
59 Comparative pharmacodynamics of CYP2B induction by DDT, DDE, and DDD in male rat liver and cultured rat hepatocytes. J Toxicol Environ Health A 1998 0.83
60 Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ 1996 0.82
61 The role of 3-OH benzo(a)pyrene in mediating benzo(a)pyrene induced toxicity and transformation in cell culture. Res Commun Chem Pathol Pharmacol 1973 0.82
62 Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice. Carcinogenesis 2001 0.82
63 Inhibition of cigarette smoke-related lipophilic DNA adducts in rat tissues by dietary oltipraz. Carcinogenesis 1998 0.82
64 P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. Cancer Res 1988 0.82
65 In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos 1997 0.82
66 Prevention of lung cancer progression by bexarotene in mouse models. Oncogene 2006 0.81
67 Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. Pharmacogenetics 1992 0.81
68 Clinical development plan: N-Acetyl-l-cysteine. J Cell Biochem Suppl 1994 0.81
69 Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res 1994 0.81
70 Mechanistic considerations in chemopreventive drug development. J Cell Biochem Suppl 1994 0.81
71 Inhibition of cigarette smoke-related DNA adducts in rat tissues by indole-3-carbinol. Mutat Res 2000 0.81
72 Relationship between DNA strand breaks and inhibition of poly (ADP-ribosylation): enhancement of carcinogen-induced transformation. Carcinogenesis 1986 0.80
73 Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1997 0.80
74 Induction of alopecia in mice exposed to cigarette smoke. Toxicol Lett 2000 0.79
75 Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis. J Cell Biochem Suppl 1996 0.79
76 Progress in clinical chemoprevention. Semin Oncol 1997 0.79
77 Induction of cytochrome P-450 in Sigmodon hispidus (cotton rats) exposed to dietary Aroclor 1254. J Toxicol Environ Health 1994 0.79
78 Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl 1995 0.79
79 Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 2000 0.79
80 Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res 1997 0.79
81 Clinical development plan: N-(4-hydroxyphenyl)retinamide. J Cell Biochem Suppl 1994 0.79
82 Effect of calcium on azoxymethane-induced aberrant crypt foci and cell proliferation in the colon of rats. Cancer Lett 1998 0.79
83 An interlaboratory comparison of transformation in Syrian hamster embryo cells with model and coded chemicals. Environ Mutagen 1986 0.79
84 Hepatic cytochrome P450 2B induction by ethyl/phenyl-substituted congeners of phenobarbital in the B6C3F1 mouse. J Biochem Toxicol 1994 0.78
85 Absence of hepatic microsomal pentyl- or benzyl-resorufin O-dealkylase induction in rainbow trout (Salmo gairdneri) treated with phenobarbitone. Biochem Pharmacol 1987 0.78
86 Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 2000 0.78
87 Effects of oral administration of tamoxifen, toremifene, dehydroepiandrosterone, and vorozole on uterine histomorphology in the rat. Proc Soc Exp Biol Med 2000 0.78
88 Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 1996 0.78
89 Tissue-specific expression of the K-ras allele from the A/J parent in (A/J x TSG-p53) F1 mice. Gene 1997 0.78
90 Effect of early vs. late administration of 4-hydroxyphenylretinamide (4-HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumorigenesis. J Cell Biochem Suppl 1997 0.78
91 Altered gene expression profile in chemically induced rat mammary adenocarcinomas and its modulation by an aromatase inhibitor. Oncogene 2001 0.78
92 Comparative activity of N-(4-hydroxyphenyl)-all-trans-retinamide and alpha-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. Carcinogenesis 1996 0.78
93 Clinical development plan: sulindac. J Cell Biochem Suppl 1994 0.78
94 Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung. J Cell Biochem Suppl 1997 0.78
95 Clinical development plan: vitamin E. J Cell Biochem Suppl 1994 0.78
96 Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. Eur J Cancer 2004 0.78
97 Oxidative metabolism of N-isopropyl-alpha-(2-methylhydrazino)-p-toluamide hydrochloride (procarbazine) by rat liver microsomes. Cancer Res 1979 0.78
98 Cytosol-mediated reduction of resorufin: a method for measuring quinone oxidoreductase. Arch Biochem Biophys 1984 0.78
99 Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats. Cancer Lett 1999 0.78
100 Clinical development plan: oltipraz. J Cell Biochem Suppl 1994 0.78
101 Expression of cell cycle proteins in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumors. Exp Lung Res 1998 0.78
102 Clinical development plan: 18beta-glycyrrhetinic acid. J Cell Biochem Suppl 1994 0.77
103 The chemopreventive agent diallyl sulfide. A structurally atypical phenobarbital-type inducer. Biochem Pharmacol 1995 0.77
104 Induction of a pleiotropic response by phenobarbital and related compounds. Response in various inbred strains of rats, response in various species and the induction of aldehyde dehydrogenase in Copenhagen rats. Biochem Pharmacol 1992 0.77
105 Regulation of gene expression of various phase I and phase II drug-metabolizing enzymes by tamoxifen in rat liver. Biochem Pharmacol 1996 0.77
106 Cytochrome P450 induction in feral Cricetid rodents: a review of field and laboratory investigations. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 0.77
107 Dose-response relationships for the induction of P450 2B by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzne (TCPOBOP) in rat and cultured rat hepatocytes. Xenobiotica 1993 0.77
108 Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis. Int J Mol Med 2000 0.77
109 Induction of immunotoxicity by polycyclic hydrocarbons: role of the Ah locus. Arch Toxicol 1984 0.77
110 Induction of immunotoxicity in mice by polyhalogenated biphenyls. Arch Toxicol 1986 0.76
111 Morphological transformation of BALB/3T3 cells by various procarcinogens in the presence of a rat liver S-9 activation system. Environ Mol Mutagen 1990 0.76
112 Comparative pharmacodynamics of CYP2B induction by phenobarbital in the male and female F344/NCr rat. Biochem Pharmacol 1993 0.76
113 Clinical development plan: piroxicam. J Cell Biochem Suppl 1994 0.76
114 Therapy of the murine plasmacytoma MOPC 104E: role of the immune response. J Natl Cancer Inst 1978 0.76
115 A method for the amplification of chemically induced transformation in C3H/10T1/2 clone 8 cells: its use as a potential screening assay. J Natl Cancer Inst 1987 0.76
116 The metabolic activation of benzo(a)pyrene and 9-hydroxybenzo(a)pyrene by liver microsomal fractions. Int J Cancer 1979 0.76
117 Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. Oncol Rep 2001 0.76
118 Tumor promoting activities of ethylphenylacetylurea and diethylacetylurea, the ring hydrolysis products of barbiturate tumor promoters phenobarbital and barbital, in rat liver and kidney initiated by N-nitrosodiethylamine. Carcinogenesis 1989 0.76
119 Clinical development plan: 2-difluoromethylornithine (DFMO). J Cell Biochem Suppl 1994 0.76
120 Relative potencies of induction of hepatic drug-metabolizing enzyme genes by individual PCB congeners. Toxicol Appl Pharmacol 1995 0.76
121 Subchronic dietary exposure to Aroclor 1254 in rats: accumulation of PCBs in liver, blood, and adipose tissue and its relationship to induction of various hepatic drug-metabolizing enzymes. Toxicol Appl Pharmacol 1994 0.76
122 Transforming growth factors-beta are not good biomarkers of chemopreventive efficacy in a preclinical breast cancer model system. Breast Cancer Res 2000 0.75
123 Induction of hepatic CYP1A in male F344/NCr rats by dietary exposure to Aroclor 1254: examination of immunochemical, RNA, catalytic, and pharmacokinetic endpoints. Environ Res 1992 0.75
124 Cytosol-mediated reduction of resorufin fluorescence: effects on the ethoxyresorufin O-deethylase (ETR) assay. Biochem Pharmacol 1983 0.75
125 The relationship of cellular metabolism of benzo(a)pyrene to the ind-uction of cytotoxicity and cell transformation in fetal hamster cells in vitro. Eur J Cancer 1975 0.75
126 Induction of alkoxyresorufin O-dealkylases, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates. Carcinogenesis 1987 0.75
127 In vitro cellular uptake of benzo(a)pyrene measured by a microfluorometric technique. Proc Soc Exp Biol Med 1971 0.75
128 Clinical development plan: ibuprofen. J Cell Biochem Suppl 1994 0.75
129 Chemical enhancement of SA7 virus transformation of hamster embryo cells: interlaboratory testing of diverse chemicals. Carcinog Compr Surv 1985 0.75
130 Interlaboratory evaluation of the C3H/10T1/2 cell transformation assay. Environ Mol Mutagen 1988 0.75
131 Liver tumor promoters and other mouse liver carcinogens. Prog Clin Biol Res 1990 0.75
132 Phenobarbital and related compounds: approaches to interspecies extrapolation. Prog Clin Biol Res 1992 0.75
133 Effect of dietary Aroclor 1254 exposure on lung and kidney cytochromes P450 in female rats: evidence for P4501A2 expression in kidney. Chem Biol Interact 1995 0.75
134 Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev 1996 0.75
135 Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 1996 0.75
136 Tumor immunity against MOPC 104E: leukocyte adherence inhibition (L.A.I.) assay. Eur J Cancer 1980 0.75
137 Clinical development plan: calcium. J Cell Biochem Suppl 1994 0.75
138 Clinical development plan: Proscar. J Cell Biochem Suppl 1994 0.75
139 Enhancement of hepatocarcinogenesis and induction of specific cytochrome P450-dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl- and 5-ethylbarbituric acids. Carcinogenesis 1994 0.75
140 Dose-response relationships for cytochrome P450 induction by phenobarbital in the cotton rat (Sigmodon hispidus). Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998 0.75
141 Influence of various parameters on benzo(a)pyrene enhancement of adenovirus SA7 transformation of Syrian hamster embryo cells. Environ Mutagen 1986 0.75
142 A comparative analysis of allelic imbalance events in chemically induced rat mammary, colon, and bladder tumors. Mol Carcinog 1999 0.75
143 Clinical development plan: beta-carotene and other carotenoids. J Cell Biochem Suppl 1994 0.75
144 An interlaboratory evaluation of the Syrian hamster embryo cell transformation assay using eighteen coded chemicals. Toxicol In Vitro 1988 0.75
145 Hepatic cytochrome P450 2B-type induction by ethyl/phenyl-substituted congeners of phenobarbital in the rat. Chem Res Toxicol 1993 0.75
146 Comparative pharmacodynamics of hepatic cytochrome P450 2B induction by 5,5-diphenyl- and 5,5-diethyl-substituted barbiturates and hydantoins in the male F344/NCr rat. J Pharmacol Exp Ther 1994 0.75
147 Induction of neoplastic transformation and DNA single-strand breaks in C3H/10T1/2 clone 8 cells by polycyclic hydrocarbons and alkylating agents. J Natl Cancer Inst 1983 0.75
148 Effects of 3-aminobenzamide on the induction of morphologic transformation by diverse compounds in Balb/3T3 cells in vitro. Carcinogenesis 1986 0.75
149 Detection of differentially expressed genes in mouse lung adenocarcinomas. Exp Lung Res 2001 0.75
150 Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity. J Natl Cancer Inst 1978 0.75
151 Analysis of the interlaboratory and intralaboratory reproducibility of the enhancement of simian adenovirus SA7 transformation of Syrian hamster embryo cells by model carcinogenic and noncarcinogenic compounds. Environ Mutagen 1986 0.75
152 Clinical development plan: vitamin D3 and analogs. J Cell Biochem Suppl 1994 0.75
153 Pharmacodynamics of cytochrome P450 2B induction by phenobarbital, 5-ethyl-5-phenylhydantoin, and 5-ethyl-5-phenyloxazolidinedione in the male rat liver or in cultured rat hepatocytes. Chem Res Toxicol 1993 0.75
154 Absence of enantioselectivity in the pharmacodynamics of P450 2B induction by 5-ethyl-5-phenylhydantoin in the male rat liver or in cultured rat hepatocytes. J Biochem Toxicol 1994 0.75
155 Clinical development plan: aspirin. J Cell Biochem Suppl 1994 0.75
156 Clinical development plan: DHEA analog 8354. J Cell Biochem Suppl 1994 0.75
157 Lack of promoting effect of clonazepam on the development of N-nitrosodiethylamine-initiated hepatocellular tumors in mice is correlated with its inability to inhibit cell-to-cell communication in mouse hepatocytes. Carcinogenesis 1989 0.75
158 Detection of differentially expressed genes in methylnitrosourea-induced rat mammary adenocarcinomas. J Cell Biochem Suppl 1997 0.75
159 Evaluation of cell proliferation in the kidneys of rodents with bromodeoxyuridine immunohistochemistry of tritiated thymidine autoradiography after exposure to renal toxins, tumor promoters, and carcinogens. Prog Clin Biol Res 1991 0.75
160 Effect of 3-aminobenzamide on the induction of toxicity and transformation by ethyl methanesulfonate and methylcholanthrene in BALB/3T3 cells. Carcinogenesis 1984 0.75
161 Effects of the oxazolidinedione anticonvulsants trimethadione and dimethadione and the barbiturate homolog 5,5-dimethylbarbituric acid on N-nitrosodiethylamine-initiated renal and hepatic carcinogenesis in the F344/NCr rat. Arch Toxicol 1992 0.75
162 Effect of high retinoid doses on RAR-beta mRNA expression in female B6D2F1 mice. Anticancer Res 2001 0.75
163 Association between susceptibility to dibenzanthracene-induced fibrosarcoma formation and the Ah locus. Int J Cancer 1983 0.75
164 Metabolic activation of benzo[a]pyrene and 9-hydorxybenzo[a]pyrene by tissue fractions from rat liver and lung [proceedings]. Biochem Soc Trans 1979 0.75
165 Accumulation and persistence of individual polychlorinated biphenyl congeners in liver, blood, and adipose tissue of rats following dietary exposure to Aroclor 1254. Arch Environ Contam Toxicol 1994 0.75
166 Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model. Carcinogenesis 1999 0.75
167 Quantitation of aryl hydrocarbon hydroxylase activity in individual fetal hamster cells in vitro. J Natl Cancer Inst 1972 0.75
168 Clinical development plan: tamoxifen. J Cell Biochem Suppl 1994 0.75